Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Apr 26, 2023 (3 years ago)

Acyclovir Oral Suspension

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Cause type: Stability / shelf life

The product degraded or failed stability testing before its labeled expiry. Heat, moisture or time can break the drug down into degradants or reduce potency. All stability / shelf life recalls.

What was recalled

Acyclovir Oral Suspension, 200mg/5mL, Rx only, Distributed by: Akorn Operating Company LLC, Gurnee, IL 60031. ALL NDCs

Drug: Acyclovir

Recalling firm
Akorn, Inc.
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0782-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Acyclovir recalls

See all
Class II · Moderate risk

Acyclovir Sodium Injection

Presence of Particulate Matter: Customer complaint for a dark red, brown and black particulate floating inside vial.

Completed Particulate / foreign matter AuroMedics Pharma LLC NDC 55150-154-10 D-0013-2023
Class III · Low risk

Acyclovir Tablets

Labeling: Incorrect or Missing Lot and/or Exp Date

Terminated Labeling / mix-up Heritage Pharmaceuticals Inc NDC 23155-227-01 D-0367-2021

Other recalls by Akorn, Inc.

All 2023 recalls